Ciaran Lawlor
Directeur des opérations chez Renagade Therapeutics, Inc.
Provenance du réseau au premier degré de Ciaran Lawlor
Entité | Type d'entité | Industrie | |
---|---|---|---|
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market.
6
| Subsidiary | Biotechnology | 6 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Ciaran Lawlor via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Comptroller/Controller/Auditor | |
Credit Suisse Securities (USA) LLC (Broker)
Credit Suisse Securities (USA) LLC (Broker) Investment Banks/BrokersFinance Credit Suisse Securities (USA) LLC (Credit Suisse Securities USA) is the broker/dealer division of Credit Suisse Securities (USA) LLC, an investment banking company headquartered in New York City. The firm was founded in 1998 and is a wholly owned subsidiary of Credit Suisse (USA), Inc., ultimately owned by Credit Suisse Group AG (SWX: CSGN) in Switzerland. Credit Suisse Securities USA offers a suite of equities, solutions and credit products and services which includes global securities sales, trading and execution, prime brokerage and comprehensive investment research. Their clients include financial institutions, corporations, governments, institutional investors, such as pension funds and hedge funds, and private individuals around the world. | Investment Banks/Brokers | Analyst-Equity | |
ORTHOFIX MEDICAL INC. | Medical Specialties | Human Resources Officer | |
ARENA PHARMACEUTICALS | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO Human Resources Officer | |
UBS Securities LLC
UBS Securities LLC Investment ManagersFinance UBS Securities LLC is an investment bank and registered broker/dealer headquartered in New York City. The firm was founded in 1998 as UBS Warburg LLC. They are a subsidiary of UBS Americas Holding LLC, ultimately held by UBS Group AG (SWX: UBSG, NYSE: UBS) in Switzerland. UBS Securities is a primary dealer in US Government securities and provides a full range of investment banking services which includes corporate finance, mergers and acquisitions, capital markets, trading and sales, fixed-income, equity research, private banking, underwriting and prime brokerage operations. The firm also provides advisory services and access to capital markets for corporate, institutional, intermediary and alternative asset management clients. | Investment Managers | Analyst-Equity | |
HALOZYME THERAPEUTICS, INC. | Biotechnology | Director of Finance/CFO | |
JPMorgan Securities LLC
JPMorgan Securities LLC Investment ManagersFinance JPMorgan Securities LLC (JPMS) is a securities brokerage firm headquartered in New York City. The firm was founded in 1985 and is a subsidiary of JPMorgan Broker-Dealer Holdings, Inc., ultimately held by JPMorgan Chase & Co., Inc. (NYSE: JPM). JPMS provides research on fixed income, credit, derivatives, emerging markets, foreign exchange, structured finance, technical analysis and bond indices. Their equity analysts cover equities throughout North America, EMEA, Asia/Pacific and the emerging markets. The firm's fixed income team formulates trading and portfolio recommendations for investors in global bonds and other fixed-income markets based on valuations, analytics and market dynamics. | Investment Managers | Analyst-Equity | |
NUVASIVE, INC. | Medical Specialties | Human Resources Officer | |
Pulmatrix Operating Co., Inc.
Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA. | Pharmaceuticals: Major | Director/Board Member | |
SHIRE | Pharmaceuticals: Major | Director of Finance/CFO | |
Cytrellis Biosystems, Inc.
Cytrellis Biosystems, Inc. Medical SpecialtiesHealth Technology Cytrellis Biosystems, Inc. designs and develops aesthetic devices. The company was founded by William Gerald Austen and Doug A. Levinson and is headquartered in Boston, MA. | Medical Specialties | Chairman | |
SPYRE THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Oxeia Biopharmaceuticals, Inc.
Oxeia Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oxeia Biopharmaceuticals, Inc. is a clinical-stage biotech company, which develops new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging. Its two indications are for (i) mild traumatic brain injury (?mTB?) known as concussion, and (ii) the cognitive decline, lethargy and ?brain-fog? associated with Covid-19 infection, known as Covid Longhauler syndrome (?Long Covid?). The company was founded in 2014 by Vishal Bansal, Amit Dilip Munshi & Kartik Kiran Shah and is headquartered in Boston, MA. | Pharmaceuticals: Major | Founder | |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
MIRATI THERAPEUTICS | Biotechnology | Director of Finance/CFO | |
Alliant International University | College/University | Graduate Degree | |
Arizona State University | College/University | Undergraduate Degree | |
Brandeis University | College/University | Undergraduate Degree | |
Hawaii Pacific University | College/University | Undergraduate Degree | |
Georgetown University | College/University | Graduate Degree | |
Harvard Medical School | College/University | Doctorate Degree | |
UCLA Anderson School of Management | College/University | Masters Business Admin | |
Peter F Drucker & Masatoshi Ito Graduate School of Management | College/University | Masters Business Admin | |
EPIRUS BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
TriNetX, LLC
TriNetX, LLC Medical/Nursing ServicesHealth Services TriNetX, Inc. provides an online data network for collaborative research. It enables hospitals, academic medical centers, physician networks, practices, and pharmaceuticals to participate in collaborative research and a public and private sustainability model for research informatics. The company was founded by Bard Geesaman in 2013 and is headquartered in Cambridge, MA. | Medical/Nursing Services | Director/Board Member | |
PMV PHARMACEUTICALS, INC. | Miscellaneous Commercial Services | Director/Board Member | |
SURFACE ONCOLOGY, INC. | Biotechnology | Director/Board Member | |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | Biotechnology | Chairman | |
Orna Therapeutics, Inc.
Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | Biotechnology | Director/Board Member Chief Executive Officer Director/Board Member | |
Aktis Oncology, Inc.
Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | Medical/Nursing Services | Chief Executive Officer Corporate Officer/Principal | |
ZURA BIO LIMITED | Biotechnology | Chairman | |
SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. IV | Financial Conglomerates | Director/Board Member | |
GALECTO, INC. | Pharmaceuticals: Major | Director/Board Member | |
PULMATRIX, INC. | Pharmaceuticals: Major | Director/Board Member | |
Bioimpact Capital LLC
Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
EVELO BIOSCIENCES, INC. | Pharmaceuticals: Major | Private Equity Investor | |
BRUKER CELLULAR ANALYSIS, INC. | Packaged Software | Human Resources Officer | |
LONGBOARD PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
CULLINAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
ALLOVIR, INC. | Biotechnology | Director/Board Member | |
ElevateBio LLC
ElevateBio LLC BiotechnologyHealth Technology ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member |
Statistiques
Internationale
Etats-Unis | 45 |
Irlande | 2 |
Royaume-Uni | 2 |
Sectorielle
Health Technology | 26 |
Finance | 9 |
Consumer Services | 9 |
Health Services | 3 |
Technology Services | 3 |
Opérationnelle
Director/Board Member | 39 |
Independent Dir/Board Member | 10 |
Corporate Officer/Principal | 9 |
Chief Executive Officer | 9 |
Private Equity Investor | 6 |
Relations les plus connectées
Insiders | |
---|---|
Amit Munshi | 27 |
Matt Roden | 18 |
Morana Jovan-Embiricos | 14 |
Laurie Stelzer | 13 |
Brian Goodman | 9 |
Lucas Vitale | 8 |
- Bourse
- Insiders
- Ciaran Lawlor
- Connexions Sociétés